Compare PTLO & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PTLO | CAPR |
|---|---|---|
| Founded | 1963 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 433.0M | 1.3B |
| IPO Year | 2021 | 2011 |
| Metric | PTLO | CAPR |
|---|---|---|
| Price | $5.27 | $30.37 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 11 | 8 |
| Target Price | $8.06 | ★ $41.38 |
| AVG Volume (30 Days) | ★ 1.4M | 1.1M |
| Earning Date | 05-28-2026 | 06-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.27 | N/A |
| Revenue | ★ $732,066,000.00 | $22,270,465.00 |
| Revenue This Year | $9.07 | N/A |
| Revenue Next Year | $6.31 | $17,308.50 |
| P/E Ratio | $19.11 | ★ N/A |
| Revenue Growth | ★ 3.03 | N/A |
| 52 Week Low | $4.41 | $4.30 |
| 52 Week High | $13.55 | $40.37 |
| Indicator | PTLO | CAPR |
|---|---|---|
| Relative Strength Index (RSI) | 48.52 | 58.57 |
| Support Level | $4.51 | $25.33 |
| Resistance Level | $5.30 | $40.37 |
| Average True Range (ATR) | 0.29 | 1.88 |
| MACD | -0.02 | 0.50 |
| Stochastic Oscillator | 38.40 | 47.91 |
Portillos Inc serves the Chicago street food industry through high-energy and multichannel restaurants designed to ignite the senses and create memorable dining experiences. It owns and operates fast-casual restaurants in the United States, along with two food production commissaries in Illinois. Its menu includes hot dogs, beef and sausage sandwiches, sandwiches and ribs, salads, burgers, chicken, Barnelli's pasta, sides and soup, and desserts and shakes.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.